Phibro Animal Health (NASDAQ:PAHC) CEO Sells $415,923.20 in Stock

Key Points

• Jack Bendheim, CEO sold 7,040 shares on April 14 at an average price of $59.08 for $415,923.20 under a pre-arranged Rule 10b5-1 plan, leaving him with 31,080 shares — an 18.47% reduction in his holdings.
• The April sale is one of many insider disposals since February involving multiple large transactions, and comes as PAHC shares slid about 2.1% to $53.88; the company recently beat quarterly EPS estimates, set FY2026 guidance of 2.93–3.10 EPS, and pays a $0.12 quarterly dividend (≈0.9% yield).

Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report) CEO Jack Bendheim sold 7,040 shares of the business's stock in a transaction on Tuesday, April 14th. The shares were sold at an average price of $59.08, for a total transaction of $415,923.20. Following the transaction, the chief executive officer owned 31,080 shares in the company, valued at approximately $1,836,206.40. This represents a 18.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jack Bendheim also recently made the following trade(s):

• On Thursday, April 16th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $54.64, for a total transaction of $384,665.60.
• On Thursday, March 19th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $52.52, for a total transaction of $369,740.80.
• On Wednesday, March 18th, Jack Bendheim sold 10,560 shares of Phibro Animal Health stock. The shares were sold at an average price of $52.68, for a total transaction of $556,300.80.
• On Tuesday, March 17th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.66, for a total transaction of $272,764.80.
• On Friday, March 13th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $48.91, for a total transaction of $258,244.80.
• On Thursday, February 26th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $53.73, for a total transaction of $378,259.20.
• On Tuesday, February 24th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.37, for a total transaction of $361,644.80.
• On Friday, February 20th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.42, for a total transaction of $361,996.80.
• On Wednesday, February 18th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.40, for a total transaction of $361,856.00.
• On Friday, February 13th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.96, for a total transaction of $365,798.40.

Phibro Animal Health Stock Down 2.1%

Shares of Phibro Animal Health stock traded down $1.13 on Thursday, hitting $53.88. 281,231 shares of the company traded hands, compared to its average volume of 311,222. The company has a 50-day moving average price of $53.29 and a 200 day moving average price of $44.96. The company has a quick ratio of 1.22, a current ratio of 3.05 and a debt-to-equity ratio of 2.14. Phibro Animal Health Corporation has a 12-month low of $16.16 and a 12-month high of $60.08. The company has a market cap of $2.18 billion, a PE ratio of 23.95, a PEG ratio of 0.84 and a beta of 0.69.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.69 by $0.18. The business had revenue of $373.91 million for the quarter, compared to analysts' expectations of $355.64 million. Phibro Animal Health had a net margin of 6.29% and a return on equity of 38.28%. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. Sell-side analysts predict that Phibro Animal Health Corporation will post 1.95 earnings per share for the current year.

Phibro Animal Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, March 25th. Investors of record on Wednesday, March 4th were issued a $0.12 dividend. The ex-dividend date was Wednesday, March 4th. This represents a $0.48 dividend on an annualized basis and a yield of 0.9%. Phibro Animal Health's dividend payout ratio is currently 21.33%.

Wall Street Analysts Forecast Growth

PAHC has been the subject of a number of recent research reports. Citigroup initiated coverage on shares of Phibro Animal Health in a report on Wednesday. They issued a "neutral" rating and a $62.00 price objective for the company. Morgan Stanley set a $49.00 price objective on shares of Phibro Animal Health in a report on Friday, February 6th. Zacks Research upgraded shares of Phibro Animal Health from a "hold" rating to a "strong-buy" rating in a report on Wednesday, March 11th. Finally, Weiss Ratings reiterated a "buy (b-)" rating on shares of Phibro Animal Health in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $42.40.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of PAHC. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Phibro Animal Health by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company's stock worth $260,000 after acquiring an additional 546 shares during the last quarter. Millennium Management LLC lifted its position in Phibro Animal Health by 74.3% during the 1st quarter. Millennium Management LLC now owns 362,030 shares of the company's stock worth $7,733,000 after acquiring an additional 154,281 shares during the last quarter. Jane Street Group LLC lifted its position in Phibro Animal Health by 65.3% during the 1st quarter. Jane Street Group LLC now owns 33,917 shares of the company's stock worth $724,000 after acquiring an additional 13,404 shares during the last quarter. Cetera Investment Advisers lifted its position in Phibro Animal Health by 63.0% during the 2nd quarter. Cetera Investment Advisers now owns 18,830 shares of the company's stock worth $481,000 after acquiring an additional 7,280 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its position in Phibro Animal Health by 2.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 13,005 shares of the company's stock worth $332,000 after acquiring an additional 363 shares during the last quarter. Institutional investors and hedge funds own 99.34% of the company's stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation NASDAQ: PAHC is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro's portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.